PR90929

MILAN, August 2, 2021, /PRNewswire=KYODO JBN/ --

ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors

unanimously appointed Avi Fischer, M.D. as Chief Executive Officer (CEO) of the

company and a member of its Board of Directors.

EPF is a medical technology company developing an innovative and uniquely

designed 'single-shot' ablation catheter system to perform pulmonary vein

isolation - the most common catheter-based procedure to treat atrial

fibrillation (Afib). Millions of patients around the world suffer from Afib,

the most common arrhythmia or abnormal heart rhythm, and hundreds of thousands

of Afib ablation procedures are performed annually.

Dr. Fischer is a Harvard trained clinician scientist, and broadly experienced

industry executive.  He most recently served as Chief Medical Officer and

Divisional Vice President, Medical Affairs for Abbott Laboratories' Cardiac

Rhythm Management (CRM) business. Prior to moving from clinical medicine to

industry, Dr. Fischer was a member of the faculty of The Mount Sinai School of

Medicine in New York City acting as Director of Pacemaker and Defibrillator

Therapy at The Mount Sinai Medical Center.  As EPF's new CEO, Dr. Fischer will

lead the company through a very important phase of growth as the catheter

ablation system enters the clinical arena as a potential treatment for AFib.

"In just two years since conception and ahead of our plan, EPF has accomplished

several important milestones, developing an extremely promising technology for

the treatment of AFib. The new CEO, Dr. Avi Fischer, brings in all of the

competencies and expertise that are now needed to lead the Company towards

clinical adoption and penetration", said Chairman of the Board, Alessandro Piga.

"I am extremely excited to take on the role of  CEO and join EPF's Board of

Directors. EPF has developed a novel "single-shot" catheter and ablation system

that aims to address a number of the challenges associated with Afib ablation.

I believe that EPF is well-positioned to accelerate its growth and begin

studying the unique catheter ablation system in clinical studies." said Dr.

Fischer

About EPF:

ElectroPhysiology Frontiers S.p.A., a company based in Italy is a medical

technology company developing an innovative 'single-shot' catheter ablation

system to simplify and improve the procedure used to isolate the pulmonary

veins for the treatment of Afib.

For further  information:   https://www.ep-frontiers.com/

Follow (https://www.ep-frontiers.com/ ) us on  Linkedin

(https://www.linkedin.com/company/75013652)

EPF Public Relations and Investor Relations

Luca Binda

operations@ep-frontiers.com

+ 39 (0) 3802566838

mail@ep-frontiers.com

Logo -

https://mma.prnewswire.com/media/1584256/ElectroPhysiology_Frontiers_Logo.jpg

SOURCE: ElectroPhysiology Frontiers S.p.A.